文献速递肿瘤 PET/CT

前列腺癌中晚期糖基化终末产物受体的定量成像

Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-12

本研究合成靶向晚期糖基化终末产物受体(RAGE)的多模态纳米颗粒64Cu-Cy5-G4-CML,在前列腺癌细胞和小鼠移植瘤中评估其靶向性与PET-CT显像效果,并用人体前列腺癌样本验证RAGE水平随Gleason评分升高而增加,提示RAGE靶向成像可行。

要点

  • 64Cu-Cy5-G4-CML在LNCaP与DU145前列腺癌细胞中显示RAGE靶向性,KD为360至540 nM。
  • 小鼠移植瘤PET-CT显示肿瘤摄取不均匀,平均摄取为0.5至1.4%ID/g,随细胞类型和肿瘤大小变化。
  • 人体前列腺癌样本中RAGE水平随Gleason评分升高而增加。

核心结论

  • RAGE靶向的癌症成像在前列腺癌中可行,并可能对前列腺癌管理产生显著影响。

研究设计与样本

  • 临床前研究:合成靶向RAGE的多模态纳米颗粒64Cu-Cy5-G4-CML,在雄激素依赖性LNCaP和雄激素非依赖性DU145前列腺癌细胞中评估结合亲和力与靶向特异性,并在DU145和LNCaP小鼠移植瘤模型中进行PET-CT显像。
  • 显像后切除肿瘤行组织学染色和放射自显影,评估RAGE水平与示踪剂靶向效率;另用不同Gleason评分的人前列腺癌样本行Western blot和免疫组化染色评估RAGE水平。

主要发现

  • 细胞培养研究以流式细胞术测得64Cu-Cy5-G4-CML的KD为360至540 nM,证实充分的RAGE靶向性。
  • 小鼠移植瘤PET-CT显像显示良好的动力学、快速血液清除和肿瘤内不均匀增强摄取,平均摄取为0.5至1.4%ID/g,随细胞类型和肿瘤大小变化。
  • 人前列腺癌样本RAGE定量证实RAGE摄取随Gleason评分升高而增加。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Current screening and monitoring of prostate cancer (PCa) is insufficient, producing inaccurate diagnoses. Presence of the receptor for advanced glycation end-products (RAGE) is associated with signature characteristics of PCa development such as cell proliferation, anchorage-independent growth, angiogenesis, migration, invasion, and poor patient survival. Therefore, we developed a preclinical multimodal imaging strategy targeted at RAGE to diagnose and monitor PCa. METHODS: In this work, RAGE-targeted multimodal nanoparticles (64Cu-Cy5-G4-CML) were synthesized and rendered functional for nuclear and optical imaging using previously established methods. The probe's binding affinity and targeting specificity was assessed in androgen-dependent (LNCaP) and androgen-independent (DU145) prostate cancer cells using flow cytometry and confocal microscopy. In vivo PET-CT imaging was used to evaluate RAGE levels in DU145 and LNCaP xenograft models in mice. Then, tumors were excised post-imaging for histological staining and autoradiography to further assess RAGE levels and targeting efficiency of the tracer. Finally, RAGE levels from human PCa samples of varying Gleason Scores were evaluated using Western blot and immunohistochemical staining. RESULTS: PCa cell culture studies confirmed adequate RAGE-targeting with 64Cu-Cy5-G4-CML with KD between 360 and 540 nM as measured by flow cytometry. In vivo PET-CT images of PCa xenografts revealed favorable kinetics, rapid blood clearance, and a non-homogenous, enhanced uptake in tumors, which varied based on cell type and tumor size with mean uptake between 0.5 and 1.4%ID/g. RAGE quantification of human samples confirmed increased RAGE uptake corresponding to increased Gleason scoring. CONCLUSIONS: Our study has shown that RAGE-targeted cancer imaging is feasible and could significantly impact PCa management.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Konopka CJ, Woźniak M, Hedhli J, et al. Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32166512. doi:10.1007/s00259-020-04721-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。